Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/6/2008

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 11:10 a.m. ET. The event will be held at the New York Palace Hotel from November 10-12, 2008.

A live audio webcast of the presentation will be available at: http://www.wsw.com/webcast/rrshq14/oncy or on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible following the presentation at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward- looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
2. Progress toward new storage media
3. Edmonton's Technology Community: Using Social Media to Raise Awareness
4. Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes
7. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
10. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
11. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... Korean researchers ... that it may offer a new way to treat the disease. Surviving Mesothelioma has ... now. , Scientists from several Korean institutions based their mesothelioma study on the ...
(Date:5/19/2016)... Ashland, Virginia (PRWEB) , ... May 19, 2016 , ... ... a new 30,000 square foot office building is complete. The new structure adds a ... In 2011, Anton Paar USA purchased 2.4 acres of land, along with ...
(Date:5/19/2016)... -- There is no saying when exactly ... pressures in pricing and lack in consumer confidence. One ... - numerous opportunities are up for grabs but this ... four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
Breaking Biology News(10 mins):